BioCryst Pharmaceuticals, Inc. (BCRX) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) trades at a price-to-earnings ratio of 7.2x, with a stock price of $8.75 and trailing twelve-month earnings per share of $1.20.
The current P/E is 11% above its 5-year average of 6.5x. Over the past five years, BCRX's P/E has ranged from a low of 6.5x to a high of 6.5x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, BCRX trades at a 69% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, BCRX trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BCRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Commercial Rare Disease Biopharma peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
VRTXVertex Pharmaceuticals Incorporated | $126B | 32.4 | 3.91 | +837% |
BMRNBioMarin Pharmaceutical Inc. | $12B | 34.3 | - | +1186%Best |
PTCTPTC Therapeutics, Inc. | $5B | 8.8 | - | +264% |
CORTCorcept Therapeutics Incorporated | $4B | 43.5 | - | -33% |
CPRXCatalyst Pharmaceuticals, Inc. | $3B | 13.7 | 0.73Best | +28% |
BCRXBioCryst Pharmaceuticals, Inc. | $2B | 7.2Lowest | - | +381% |
HRMYHarmony Biosciences Holdings, Inc. | $2B | 10.5 | - | +8% |
PLXProtalix BioTherapeutics, Inc. | $218M | 78.7 | - | -63% |
SLNOSoleno Therapeutics, Inc. | $145,692 | 100.2 | - | +109% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $7.80 | $1.20 | 6.5x | +0% |
Average P/E for displayed period: 6.5x
See BCRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCRX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BCRX vs AGIO
See how BCRX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BCRX stock overvalued or undervalued?
BCRX trades at 7.2x P/E, near its 5-year average of 6.5x. The 100th percentile ranking places valuation within normal historical bounds.
How does BCRX's valuation compare to peers?
BioCryst Pharmaceuticals, Inc. P/E of 7.2x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is BCRX's PEG ratio?
BCRX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.